8-K: Semper Paratus Acquisition Corporation Shareholders Approve Merger with Tevogen Bio

Semper Paratus Acquisition Corporation shareholders have approved the proposed business combination with Tevogen Bio, paving the way for the merger to be completed.

Summary

• Semper Paratus Acquisition Corporation held an extraordinary general meeting on January 31, 2024, where shareholders voted to approve the merger with Tevogen Bio.
• All proposals related to the merger, including the domestication of Semper Paratus to Delaware and the change of name to Tevogen Bio Holdings Inc., were approved.
• Approximately 1.43 million shares were redeemed by shareholders for a total of about $15.9 million, or $11.07 per share, from the trust account.
• The combined company's common stock is expected to trade on Nasdaq under the symbols TVGN and TVGNW.
• The merger is expected to be completed as soon as practicable after remaining closing conditions are met, including Nasdaq listing approval.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the successful shareholder vote and progress towards the merger. However, the high redemption rate and the inherent risks of a clinical-stage biotech company temper the overall sentiment.

Positives

• Shareholder approval was secured for all proposals related to the merger, indicating strong support for the transaction.
• The merger is progressing towards completion, with the combined company expected to be listed on Nasdaq.
• Tevogen Bio is a clinical-stage immunotherapy company with a focus on innovative T-cell therapies.
• Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial.
• Tevogen Bio owns key intellectual property assets, including granted and pending patents.

Negatives

• A significant number of shares were redeemed, resulting in approximately $15.9 million being removed from the trust account.
• The merger is still subject to remaining closing conditions, including Nasdaq listing approval, which introduces some uncertainty.
• Tevogen Bio has a limited operating history and no products approved for commercial sale, which presents risks.
• The company is subject to the lengthy and time-consuming FDA regulatory approval process.

Risks

• The business combination may not be completed in a timely manner or at all.
• Failure to meet closing conditions could terminate the merger agreement.
• There is a risk of not achieving sufficient cash after redemptions.
• The combined company may fail to meet Nasdaq listing standards.
• The anticipated benefits of the merger may not be realized due to competition or other factors.
• There is potential for litigation related to the proposed transaction.
• Estimates of the combined company's financial performance may be incorrect.
• Changes in economic or political conditions could negatively impact the company.
• Tevogen Bio's approach to product development is unproven.

Future Outlook

The combined company, Tevogen Bio Holdings Inc., is expected to begin trading on Nasdaq under the symbols TVGN and TVGNW after the merger is completed. The company anticipates growth in the immunotherapy sector, focusing on T-cell therapies for infectious diseases, cancers, and neurological disorders.

Management Comments

• Semper Paratus Chief Executive Officer Surendra Ajjarapu stated 'We have cleared yet another hurdle to closing our business combination with Tevogen Bio, and we will continue to work diligently with Tevogen Bio to satisfy the remaining closing conditions.'

Industry Context

This merger reflects a trend of special purpose acquisition companies (SPACs) merging with private companies, particularly in the biotech sector. Tevogen Bio's focus on T-cell therapies aligns with the growing interest in personalized medicine and immunotherapy, which are areas of significant investment and research in the pharmaceutical industry.

Comparison to Industry Standards

• The redemption rate of approximately 95% of public shares is relatively high compared to other SPAC mergers, which may indicate some shareholder uncertainty about the deal.
• The valuation of Tevogen Bio will be determined by the market once it begins trading on Nasdaq, and will be compared to other clinical-stage biotech companies such as Adaptimmune Therapeutics and Allogene Therapeutics.
• The success of the merger will depend on Tevogen Bio's ability to advance its clinical trials and obtain regulatory approvals, which is a common challenge for companies in this sector.

Stakeholder Impact

• Shareholders of Semper Paratus have the option to redeem their shares or become shareholders of the combined company.
• Employees of both Semper Paratus and Tevogen Bio will be impacted by the merger.
• Customers and suppliers of Tevogen Bio will be impacted by the merger and the future direction of the company.
• Creditors of both companies will be impacted by the merger.

Next Steps

• The remaining closing conditions for the merger must be satisfied or waived.
• The combined company's common stock needs to be approved for listing on Nasdaq.
• The trustee of the Trust Account will finalize the amount of funds to be removed for redemptions.
• The combined company will begin trading on Nasdaq under the symbols TVGN and TVGNW.

Key Dates

Keywords

Merger, Acquisition, Business Combination, SPAC, Tevogen Bio, Semper Paratus, Nasdaq, Redemption, Immunotherapy, Shareholder Approval